Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...
Prescription drug spending in the United States has been on a steady rise for years, with Americans paying some of the ...
A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous ...
For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...
Per deal terms, Novo will have commercialization rights to the drug outside of China and nearby marketing territories, and ...
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee ...
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee ...
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it. The agency’s Committee ...
European Committee Says Lilly Alzheimer's Drug Shouldn't Get Marketing Approval A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback